Related Experiment Video
Updated: May 13, 2026

Pre-clinical Model of Cardiac Donation after Circulatory Death
Published on: August 2, 2019
Potential pool of cardiothoracic organs from donors with HIV
Mary G Bowring1, Jessica M Ruck1, Zeba Nauroz1
1Johns Hopkins University School of Medicine, Baltimore, MD.
Insights
Expanding organ donation from HIV-positive donors to include heart and lung transplants could significantly increase the availability of life-saving cardiothoracic organs for HIV-positive recipients. This research highlights the potential for increased heart and lung transplants under the HIV Organ Policy Equity (HOPE) Act.
Area of Science:
- Transplantation immunology
- Infectious disease research
- Public health policy
Background:
- The HIV Organ Policy Equity (HOPE) Act initially limited HIV-positive to HIV-positive (HIV D+/R+) transplants to kidney and liver.
- Recent guideline modifications permit broader cardiothoracic program involvement in HIV D+/R+ transplants.
Purpose of the Study:
- To estimate the number of potential cardiothoracic organ donors among individuals with HIV.
- To assess the feasibility of expanding HIV D+/R+ transplantation to include heart and lung organs.
Main Methods:
- Utilized Scientific Registry of Transplant Recipients (SRTR) data from March 2016 to December 2024.
- Developed a logistic regression model to predict cardiothoracic donation probability based on kidney/liver donation in donors without HIV.
- Applied the model to estimate potential cardiothoracic donors among existing HIV Organ Policy Equity (HOPE) Act donors.
Main Results:
- An estimated 41.0% of HOPE donors were potential heart donors, and 18.7% were potential lung donors.
- This could translate to an annual 13-18 heart and 5-8 lung transplants from HOPE donors.
- Cardiothoracic donation among donors without HIV was associated with factors including age, cause of death, and comorbidities like hypertension and diabetes.
Conclusions:
- Expanding HIV D+/R+ transplantation to cardiothoracic organs could utilize a significant portion of existing HOPE donors.
- Approximately 41% of HOPE kidney and liver donors could potentially donate a heart, and nearly 20% could donate a lung.
- This expansion offers a promising avenue to increase organ availability for HIV-positive candidates awaiting heart or lung transplants.
Background:
Under the HIV Organ Policy Equity (HOPE) Act, transplants from donors with HIV to recipients with HIV (HIV D+/R+) have been largely limited to kidney and liver. However, recent modifications to HOPE research guidelines allow broader participation of cardiothoracic programs.
Methods:
To quantify potential cardiothoracic HOPE donors, we used Scientific Registry of Transplant Recipients (SRTR) data (3/2016-12/2024) to identify 101,200 donors without HIV and 273 HOPE donors (with true and false positive HIV tests). Using logistic regression, we predicted the probability of having a heart or lung(s) used for transplant among donors without HIV that had a kidney or liver used. We then applied model parameters to HOPE donors that had a kidney or liver used to estimate the number of HOPE donors that might have been cardiothoracic donors if the practice were expanded.
Results:
Among donors without HIV, cardiothoracic donation was associated with age, cause of death, hepatitis C, hypertension, diabetes, smoking, cardiovascular disease, blood gas, and circulatory death. Applying our model, an estimated 41.0% (N = 111), 18.7% (N = 51), and 15.2% (N = 41) of HOPE donors were potential heart, any lung (single or double), or double-lung donors, as compared to 32.3%, 21.8%, and 18.2% of abdominal organ donors without HIV, respectively. This translated to an annual 13-18 potential heart and 5-8 potential lung transplants (of which 4-6 would be double-lung transplants) from HOPE donors.
Conclusions:
If HIV D+/R+ is more widely expanded to cardiothoracic transplantation, 41% of HOPE kidney and liver donors have the potential to donate a heart and almost 20% to donate a lung to candidates with HIV.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Kidney Transplant I: Introduction

